Altimmune Draws $10 Million From Hercules Loan, Pushing Interest-Only Period To June 2028
The draw on a $125.0 million facility also sets a minimum cash floor equal to 60% of outstanding loan principal.
Altimmune, the late clinical-stage drug developer behind the liver-disease candidate pemvidutide, drew $10.0 million on Tuesday from its Hercules Capital loan, an 8-K filed Thursday shows. The draw pushes the start of principal repayments out to June 1, 2028 and sets a cash floor of 60% of the loan principal.
Terms of the third tranche
The money, labeled Tranche Three, comes from a $125.0 million Loan and Security Agreement dated May 13, 2025, with Hercules Capital and other lenders. The agreement was amended on November 5, 2025.
The tranche became available once Altimmune met certain clinical and financial milestones set out in the agreement. Meeting that milestone extended the amortization date, when principal repayment begins, and the interest-only period to June 1, 2028.
The cost of the draw includes a 1.0% Tranche Facility Charge, which was netted from the funding. The end-of-term charge stays at 6.25% of the amounts funded.
A cash floor tied to the debt
The same milestone brings a minimum cash covenant into play. Altimmune must keep Qualified Cash at or above the outstanding principal of its term loan advances multiplied by 60%.
The cash requirement therefore moves with the amount borrowed, so the draw raises the balance the company has to keep on hand.
A late-stage biotech adds directors
Altimmune has no approved products. Its lead candidate, pemvidutide, is a once-weekly injected peptide that activates glucagon and GLP-1 receptors. It is being tested in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease, and it holds FDA Breakthrough Therapy and Fast Track designations for MASH.
On Tuesday the company also said it is adding Peter Greenleaf and Alex Howarth to its board as it moves into late-stage development. A Phase 3 MASH trial of pemvidutide is funded and ongoing.
Greenleaf and Howarth join the Altimmune board effective November 2.
Sources
- 8-K Filing — Altimmune, Inc. (ALT) — SEC EDGAR
- Altimmune Appoints Peter Greenleaf and Alex Howarth, Two — globenewswire.com